1. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–37.
https://doi.org/10.1002/cncr.29936
.
2. Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD,
https://seer.cancer.gov/csr/1975_2014/
, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
3. Qiang G, Guo Y, Xiao F, Yu Q, Liang C, Song Z, et al. Analyses of risk factors for postoperative recurrence after curative resection of stage III A-N2 non-small cell lung cancer. Zhonghua Yi Xue Za Zhi. 2014;94(41):3239–43.
4. Goldstraw PI, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung Cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.
5. Administration USFaD. FDA expands approved use of Opdivo in advanced lung cancer. FDA. 2015.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm
. Accessed 25 April 2017.